Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 18/20 | 0.75 |
| ▸ | MTOR | P42345 | 1/20 | 0.70 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.48 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.48 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.48 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.48 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.48 |
| ▸ | FASN | P49327 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3762430 | 0.97 | PIK3CA (0.77) | PIK3CAMTORBMPR1BBMPR1ATGFBR1 | |
| SCHEMBL3757217 | 0.88 | PIK3CA (0.81) | PIK3CAMTOR | |
| SCHEMBL3758133 | 0.86 | PIK3CA (0.74) | PIK3CAMTORFASN | |
| SCHEMBL3759962 | 0.86 | PIK3CA (0.71) | PIK3CAMTORFASN | |
| SCHEMBL3750091 | 0.86 | PIK3CA (0.82) | PIK3CAMTORFASN | |
| SCHEMBL3753823 | 0.85 | PIK3CA (0.77) | PIK3CAMTORFASN | |
| SCHEMBL3756025 | 0.84 | PIK3CA (0.78) | PIK3CAMTORFASN | |
| SCHEMBL3760483 | 0.83 | PIK3CA (0.77) | PIK3CAMTORFASN | |
| SCHEMBL3754202 | 0.83 | PIK3CA (0.83) | PIK3CAMTORFASN | |
| SCHEMBL3752987 | 0.83 | PIK3CA (0.79) | PIK3CAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| WO-2010118208-A1 | BENZOXAZEPIN-4- (5H) -YL DERIVATIVES AND THEIR USE TO TREAT CANCER | EXELIXIS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | MTOR, RICTOR, RPTOR | PIK3CA 16/4885MTOR 1/4885BMPR1B 3555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.